AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Pacira BioSciences Rises 0.07% on Strong Earnings
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Sep 2, 2025 5:59 am ET1min read
Aime SummaryOn September 2, 2025,
saw a modest rise of 0.07% in pre-market trading, indicating a slight positive sentiment among investors.Pacira BioSciences, Inc. is a company focused on developing and marketing non-opioid pain management and regenerative health solutions. Its flagship product, EXPAREL, provides postsurgical analgesia and reduces the consumption of opioid medications. The company's iovera system is a non-opioid handheld cryoanalgesia device used to produce precise, controlled doses of cold temperature to targeted nerves, offering a non-pharmacological approach to pain management.
Recently, Pacira BioSciences reported strong second-quarter earnings, surpassing analysts' estimates. This positive financial performance has likely contributed to the recent market sentiment, as investors recognize the company's ability to deliver on its financial goals. The company's market capitalization stands at approximately $1.19 billion USD, reflecting its position as a mid-sized player in the pharmaceutical industry.
Analysts have rated Pacira BioSciences as a "Buy" with a 12-month target price of $29.00, indicating an 8.74% upside from the current price. This optimistic outlook is supported by the company's innovative product portfolio and its commitment to non-opioid pain management solutions, which are increasingly in demand as the healthcare industry seeks alternatives to opioid-based treatments.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Dakota Gold DC shares plummeted 6.90% as mining stocks selloff follows sharp gold silver price declines
Dec.30 2025
Integra Resources shares plunge 9.58% on Dec. 30 2025 as project delays regulatory uncertainties spook investors
Dec.30 2025
AXT shares fell 5.07% in pre-market trading on Dec. 30 2025 amid sector pressures and speculative positioning adjustments.
Dec.30 2025
Autozi Internet shares surged 8.76% on strategic AI pivot and regulatory progress
Dec.30 2025
ProKidney shares plunged 13.04% due to regulatory scrutiny and operational concerns
Dec.30 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet